^
    6ms
    Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors (PRNewswire)
    "Illumina Inc...announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available, or to complement tissue-based testing....Expected in the first half of 2024, automation-enabled kits and method for TSO 500 ctDNA v2 will allow laboratories to scale with the growing demand for this technology."
    Launch
    |
    TruSight Oncology 500 ctDNA v2
    7ms
    Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling (ESMO Asia 2023)
    Conclusions Fusions detected from ctDNA CGP showed promising clinical utility based on the observed response to the targeted agents. Adjustments in the cutoff and correction of the effect from tumor fraction is required for ctDNA-derived TMB/MSI.
    Clinical • Tumor mutational burden • Circulating tumor DNA • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2)
    |
    MSI-H/dMMR • FGFR2 fusion • ALK fusion
    |
    TruSight Oncology 500 Assay • TruSight Oncology 500 ctDNA v2